Dextech Medical

Dextech Medical EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Dextech Medical (DEX.SL) as of Nov 2, 2026 is -32.44. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -40.56 — a change of -20.01% (higher).

EV/EBIT

-32.44

YoY

-20.01%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Dextech Medical is 2026 -32.44 . EV/EBIT (Enterprise Value to EBIT) of Dextech Medical was 2025 -40.56 . It decreases by -20.01% higher compared to the previous year.

The Dextech Medical EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-25.81 SEK
Jan 1, 2020
-27.96 SEK
Jan 1, 2021
-35.50 SEK
Jan 1, 2022
-40.93 SEK
Jan 1, 2023
-43.67 SEK
Jan 1, 2024
-38.87 SEK
Jan 1, 2025
-40.56 SEK
Jan 1, 2026
-32.44 SEK
The Dextech Medical EV/EBIT history
YEAREV/EBITYoY
-32.44-20.01%
-40.56+4.34%
-38.87-10.99%
-43.67+6.69%
-40.93+15.29%
-35.50+26.97%
-27.96+8.32%
-25.81+5.47%
-24.47-10.63%
-27.39-22.83%
-35.49-8.28%
-38.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dextech Medical Stock analysis

What does Dextech Medical do? Dextech Medical AB develops drug candidates for urological oncology, focusing on prostate cancer and other conditions. The company utilizes its patented GuaDex technology platform to create modified carbohydrate molecules combined with active substances. Its portfolio includes OsteoDex for bone metastases in castration-resistant prostate cancer, SomaDex targeting acromegaly and neuroendocrine tumors, and CatDex for bladder cancer treatment. The company holds patents or patent applications for these three drug candidates. Dextech Medical AB's primary revenue streams come from licensing its technology and drug candidates to pharmaceutical partners. The company's GuaDex platform and its drug candidates, OsteoDex, SomaDex, and CatDex, are marketed to biopharmaceutical companies seeking innovative treatments for urological oncology and related diseases. The firm's focus on prostate cancer, bone metastases, and bladder cancer creates a targeted market for its products. The company's business model relies on developing and commercializing its drug candidates through partnerships with established pharmaceutical companies. With only three drug candidates in its portfolio, Dextech Medical AB targets specific therapeutic areas within urological oncology, leveraging its patented GuaDex platform to attract potential partners in the biopharmaceutical industry. Dextech Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dextech Medical stock

EV/EBIT (Enterprise Value to EBIT) of Dextech Medical is -32.44 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Dextech Medical changed from -40.56 to -32.44, representing a -20.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Dextech Medical since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Dextech Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Dextech Medical

All Key Metrics — Dextech Medical